Evaluation of the relationship between previous statin use and thyroid cancer using Korean National Health Insurance Service-Health Screening Cohort data.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 04 2021
12 04 2021
Historique:
received:
12
11
2020
accepted:
26
03
2021
entrez:
13
4
2021
pubmed:
14
4
2021
medline:
4
11
2021
Statut:
epublish
Résumé
The association of thyroid cancer with statin use is controversial. This study aimed to investigate the association of previous statin use with thyroid cancer in the ≥ 40-year-old population in the Korean National Health Insurance Service-Health Screening Cohort. The 5501 patients in the thyroid cancer group were matched with the 22,004 patients in the non-thyroid cancer group for age, sex, income, and region of residence. Previous statin use during the 2 years before the diagnosis of thyroid cancer was examined. The odds ratios (ORs) with 95% confidence intervals (CIs) of previous statin use for thyroid cancer were estimated using conditional logistic regression analyses. Additionally, subgroup analyses were conducted. The thyroid cancer group showed more days of previous statin use than the non-thyroid cancer group (72.3, standard deviation [SD] = 181.2 days vs. 64.3, SD = 174.4 days, P = 0.003). Although the odds of previous statin use for thyroid cancer were high in the crude model (OR = 1.10, 95% CI 1.04-1.17, P = 0.002), they were low in the fully adjusted model (OR = 0.89, 95% CI 0.82-0.95, P = 0.001). According to age and sex subgroups, the younger (< 60 years old) male group showed lower odds for thyroid cancer according to previous statin use (adjusted OR = 0.70, 95% CI 0.55-0.88, P = 0.003), but this finding was not observed in other subgroups of older men or in any groups of women. Thyroid cancer was negatively associated with statin use in the previous 2 years in the adjusted model.
Identifiants
pubmed: 33846511
doi: 10.1038/s41598-021-87297-6
pii: 10.1038/s41598-021-87297-6
pmc: PMC8041859
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7912Références
JAMA. 2019 Dec 24;322(24):2441-2443
pubmed: 31860036
J Allergy Clin Immunol Pract. 2020 Mar;8(3):1005-1013.e9
pubmed: 31733335
Anticancer Agents Med Chem. 2014 Jun;14(5):706-12
pubmed: 24295174
Obes Rev. 2013 Dec;14(12):1006-22
pubmed: 24034423
Otolaryngol Head Neck Surg. 2019 Feb;160(2):239-245
pubmed: 30274554
Sci Rep. 2020 Mar 6;10(1):4248
pubmed: 32144385
Pharmacol Res. 2014 Oct;88:3-11
pubmed: 24657242
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Nutr Metab Cardiovasc Dis. 2019 Jul;29(7):701-709
pubmed: 31133496
BMJ. 2010 May 20;340:c2197
pubmed: 20488911
Cancer Causes Control. 2014 Sep;25(9):1187-95
pubmed: 24981099
Eur J Clin Pharmacol. 2020 Dec;76(12):1639-1651
pubmed: 32719919
Cell Physiol Biochem. 2018;47(4):1422-1431
pubmed: 29929194
Breast Cancer Res Treat. 2020 Aug;183(1):153-160
pubmed: 32572715
Cancer Res Treat. 2017 Jan;49(1):70-78
pubmed: 27338034
J Clin Endocrinol Metab. 2001 Mar;86(3):1072-7
pubmed: 11238488
Int J Mol Sci. 2018 Jun 22;19(7):
pubmed: 29932104
IUBMB Life. 2016 Feb;68(2):85-96
pubmed: 26707588
Thyroid. 2007 Sep;17(9):903
pubmed: 17956167
Biochem Biophys Res Commun. 1996 Mar 27;220(3):864-70
pubmed: 8607857
N Engl J Med. 2014 Nov 6;371(19):1765-7
pubmed: 25372084
Nat Clin Pract Endocrinol Metab. 2008 May;4(5):242-3
pubmed: 18301396
Clin Endocrinol (Oxf). 2015 Jul;83(1):111-6
pubmed: 25074346
PLoS One. 2018 Mar 29;13(3):e0195074
pubmed: 29596481
J Clin Med. 2020 Jan 23;9(2):
pubmed: 31979352
JAMA. 2020 Jul 7;324(1):68-78
pubmed: 32633800
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
Clin Endocrinol (Oxf). 2008 Jan;68(1):16-21
pubmed: 17666091
J Intern Med. 2018 Oct;284(4):346-357
pubmed: 29923256
Menopause. 2019 Dec;26(12):1425-1435
pubmed: 31513091
Horm Cancer. 2018 Apr;9(2):108-116
pubmed: 29352404
Int J Clin Pharmacol Ther. 2004 Dec;42(12):695-700
pubmed: 15624286
Biochim Biophys Acta Biomembr. 2020 Sep 1;1862(9):183306
pubmed: 32302615
Clin Exp Otorhinolaryngol. 2019 Nov;12(4):412-419
pubmed: 31079445
Pharmacol Res. 2018 Sep;135:230-238
pubmed: 30120976
Pharmacol Res. 2019 Nov;149:104469
pubmed: 31577918